Chapter 58. Pemphigus

  1. Hywel Williams MSC, PhD, FRCP Professor Dermato-Epidemiology Co-ordinating Editor
  1. Brian R. Sperber MD, PhD1,
  2. Linda K. Martin MBBS Dermatology Fellow2,
  3. Dedee F. Murrell MA, BMBCh, MD, FAAD Chair Associate Professor2,3 and
  4. Victoria P. Werth MD Professor of Dermatology and Medicine4

Published Online: 14 JAN 2009

DOI: 10.1002/9781444300161.ch58

Evidence-Based Dermatology, Second Edition

Evidence-Based Dermatology, Second Edition

How to Cite

Sperber, B. R., Martin, L. K., Murrell, D. F. and Werth, V. P. (2008) Pemphigus, in Evidence-Based Dermatology, Second Edition (ed H. Williams), Blackwell Publishing Ltd., Oxford, UK. doi: 10.1002/9781444300161.ch58

Editor Information

  1. Centre of Evidence-Based Dermatology, Nottingham University Hospital NHS Trust, Queen's Medical Centre, Nottingham, UK

Author Information

  1. 1

    Private Practice, Colorado Springs, Colorado, CO, USA

  2. 2

    Department of Dermatology, St George Hospital, Sydney, Australia

  3. 3

    University of New South Wales Medical School, Sydney, Australia

  4. 4

    University of Pennsylvania School of Medicine, Philadelphia, PA, USA

Publication History

  1. Published Online: 14 JAN 2009
  2. Published Print: 11 APR 2008

ISBN Information

Print ISBN: 9781405145183

Online ISBN: 9781444300161



  • Pemphigus - intra-epidermal autoimmune blistering disease;
  • Pemphigus and T-cell–driven autoantibody-mediated disease;
  • enzyme-linked immunosorbent assay (ELISA) - new diagnostic modality and prognostic indicator;
  • immunosuppressive medications;
  • adjuvant oral cyclophosphamide in combination with corticosteroids;
  • mycophenolate mofetil - immunosuppressive drug with adverse effects;
  • pulsed intravenous cyclophosphamide in lupus nephritis;
  • immunoadsorption in pemphigus;
  • anti-inflammatory agents - beneficial in mild or steroiddependent disease


This chapter contains sections titled:

  • Background

  • Questions

  • References